Faculty

Kristopher R. Bosse, MD

Assistant Professor of Pediatrics (Oncology)

Department: Pediatrics

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Children's Hospital of Philadelphia
3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104

Office: 651-492-6726
Fax: 267-426-0685

Email:
bossek@chop.edu

Education:
BA (Biochemistry )
Bowdoin College, 2002.
MD (Medicine)
University of Pennsylvania School of Medicine, 2010.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Bosse KR, Wray L, Varghese M, Giudice A, Roth S, Matlaga S, Gladney W, Nguyen Mau S-M, Vultur A, McIntyre B, Martinez D, Sparrow A, Dinofia A, Gallagher D, Pogoriler J, Kreiger P, Takeda M, Barrett D, Davis JC, States LJ, Mosse Y, Gonzales V, Fraietta JA, Grupp S, Maris JM. : Safety and efficacy in a first-in-human GPC2 CAR T cell phase 1 trial for neuroblastoma. Plenary Talk Presented at the Advances in Neuroblastoma Research Congress May 2025.

Spear TT (presenter), Samata M, Pastor S, Patel K, Farrel A, Posthill E, Groff D, Giudice AM, Bosse KR, Wang T, Liu L, Wang R, Maris JM.: A tractable immune competent neuroblastoma murine model for immunoncology (IO) preclinical studies. Presented at the Advances in Neuroblastoma Research Congress May 2025.

Narch A, Shapiro M, Mishra P, Jung P, Bayingana K, Dessau JL, Dong MM, Patel A, Bosse KR, Dang CV, Wolpaw AJ (presenter). : Targeting lineage heterogeneity in neuroblastoma via cGAS-STING. Parallel Talk Presented at the Advances in Neuroblastoma Research Congress May 2025.

Giudice AM, Roth S (Presenter), Matlaga A, Cresswell-clay E, Schürch PM, Samanta M, Pascual-Pasto G, Spear T, McIntyre B, Mishra P, Chada N, Wang R, Wilson JT, Wolpaw AJ, Bosse KR. : Reprogramming the immunosuppressive tumor microenvironment by armoring GPC2 CAR T cells with CXCR2. Presented at the Advances in Neuroblastoma Research Congress May 2025.

Shapiro M (presenter), Narch A, Mishra P, Jung P, Bayingana K, Bosse KR, Wolpaw AJ.: A CRISPR-Cas9 screen uncovers lineage state-specific regulation of inflammatory signaling. Presented at the Advances in Neuroblastoma Research Congress May 2025.

Schürch PM (presenter), Zecchino VP, Giudice AM, Mcintyre BC, Roth S, Kaufman R, Shraim R, Hamilton AK, Pascual-Pasto G, Mishra P, Groff D, Martinez D, Li W, Diskin SJ, Bosse K. : The super-enhancer driven nicotinic acetylcholine α3β4 receptor complex as an immunotherapeutic target in high-risk neuroblastoma. Plenary Talk Presented at the Advances in Neuroblastoma Research Congress May 2025.

Strijker JGM*, Pascual-Pasto G*, Grothusen GP, Kalmeijer YJ, Kalaitsidou E, Zhao C, McIntyre B, Matlaga S, Visser LL, Barisa M, Himsworth C, Shah R, Muller H, Schild LG, Hains PG, Zhong Q, Reddel R, Robinson PJ, Catena X, Soengas MS, Margaritis T, Dekker FJ, Anderson J, Molenaar JJ, Bosse KR*, Wu W*, Wienke J*. *, these authors contributed equally. : Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. European Journal of Cancer January 2025.

Turn, C, Wolpaw A, Bosse KR: Neuroblastoma. Ferri’s Clinical Advisor 2025.

Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ.: A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell October 2024.

Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, Mishra P, Matlaga S, Lombardi S, Shraim R, Schürch PM, Yarmarkovich M, Hofmann TJ, Alikarami F, Martinez D, Tsang M, Gil-de-Gómez L, Spear TT, Bernt K, Wolpaw AJ, Dimitrov DD, Li W, Bosse KR.: CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nature Communications August 2024.